In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 310, Issue 9, 2016, Pages R866-R874

  Toräng, Signe ^a   Bojsen Møller, Kirstine Nyvold ^a,b   Svane, Maria Saur ^a,b   Hartmann, Bolette ^a   Rosenkilde, Mette Marie ^a   Madsbad, Sten ^a,b   Holst, Jens Juul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Degradation; Kinetics; Peptide YY

Indexed keywords

NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; PEPTIDE YY [3-34]; PEPTIDE YY [3-36]; SITAGLIPTIN; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DEGRADATION; ELIMINATION HALF-LIFE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; METABOLIC CLEARANCE RATE; METABOLITE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ANIMAL; BLOOD PRESSURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS CELL LINE; GLUCOSE BLOOD LEVEL; METABOLISM; PROTEIN DEGRADATION; YOUNG ADULT;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDE YY; PROTEOLYSIS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84984660098     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00394.2015     Document Type: Article

References (37)

1. Abid K, Rochat B, Lassahn PG, Stöcklin R, Michalet S, Brakch N, Aubert JF, Vatansever B, Tella P, Meester ID, Grouzmann E. Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35. A new peptide generated by plasma kallikrein. J Biol Chem 284: 24715-24724, 2009.
2. Addison ML, Minnion JS, Shillito JC, Suzuki K, Tan TM, Field BCT, Germain-Zito N, Becker-Pauly C, Ghatei MA, Bloom SR, Murphy KG. A role for metalloendopeptidases in the breakdown of the gut hormone, PYY3-36. Endocrinology 152: 4630-4640, 2011.
3. Adrian TE, Bacarese-Hamilton AJ, Smith HA, Chohan P, Manolas KJ, Bloom SR. Distribution and postprandial release of porcine peptide YY. J Endocrinol 113: 11-14, 1987.
4. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89: 1070-1077, 1985.
5. Adrian TE, Sagor GR, Savage AP, Bacarese-Hamilton AJ, Hall GM, Bloom SR. Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. J Clin Endocrinol Metab 63: 803-807, 1986.
6. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941-948, 2003.
7. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY[sub3-36] physiologically inhibits food intake. Nature 418: 650, 2002.
8. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, Le Roux CW, Thomas EL, Bell JD, Withers DJ. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4: 223-233, 2006.
9. Beck-Sickinger AG, Weland HA, Wittneben H, Willim KD, Rudolf K, Jung G. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur J Biochem 225: 947-958, 1994.
10. Bertrand G, Gross R, Roye M, Ahrkn B, Ribes G. Evidence for a direct inhibitory effect of PYY on insulin secretion in rats. Pancreas 7: 595-600, 1992.
11. Boey D, Lin S, Karl T, Baldock P, Lee N, Enriquez R, Couzens M, Slack K, Dallmann R, Sainsbury A, Herzog H. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49: 1360-1370, 2006.
12. Bottcher G, Ahren B, Lundquist I, Sundler F. Peptide YY: Intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 4: 282-288, 1989.
13. Burcelin R, Brunner HR, Seydoux J, Thorensa B, Pedrazzini T. Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides 22: 421-427, 2001.
14. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957, 1995.
15. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85: 3575-3581, 2000.
16. Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129: 1430-1436, 2005.
17. Glover ID, Barlow DJ, Pitts JE, Wood SP, Tickle IJ, Blundell TL, Tatemoto K, Kimmel JR, Wollmer A, Strassburger W, Zhang YS. Conformational studies on the pancreatic polypeptide hormone family. Eur J Biochem 142: 379-385, 1984.
18. Greeley GH, Hashimoto T, Izukura M, Gomez G, Jeng J, Hill FLC, Lluis F, Thompson JC. A comparison of intraduodenally and intracolonically administered nutrients on the release of peptide-YY in the dog. Endocrinology 125: 1761-1765, 1989.
19. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. In vivo and in vitro degradation of glucagonlike peptide-2 in humans. J Clin Endocrinol Metab 85: 2884-2888, 2000.
20. Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression. In: Methods in Neurosciences, edited by Conn PM. New York, NY: Academic, 2015, p. 3-22.
21. Keire DA, Kobayashi M, Solomon TE, Reeve JR. Solution structure of monomeric peptide YY supports the functional significance of the PP-fold. Biochemistry 39: 9935-9942, 2000.
22. Khan IU, Reppich R, Beck-Sickinger AG. Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability. Biopolymers 88: 182-189, 2007.
23. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
24. Kirby DA, Boublik JH, Rivier JE. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions. J Med Chem 36: 3802-3808, 1993.
25. Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179: 91-100, 2012.
26. Kostenis E. Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci 22: 560-564, 2001.
27. Le Roux CW, Batterham RL, Aylwin SJB, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3-8, 2006.
28. Le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem 45: 93-95, 2008.
29. Lindner D, Stichel J, Beck-Sickinger AG. Molecular recognition of the NPY hormone family by their receptors. Nutrition 24: 907-917, 2008.
30. Medeiros MD, Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24. 11. Endocrinology 134: 2088-2094, 1994.
31. Rosenkilde MM, Kledal TN, Schwartz TW. High constitutive activity of a virus-encoded seven transmembrane receptor in the absence of the conserved DRY motif (Asp-Arg-Tyr) in transmembrane helix 3. Mol Pharmacol 68: 11-19, 2005.
32. Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A, Sjödin A. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab 306: E1248-E1256, 2014.
33. Shi YC, Lin Z, Lau J, Zhang H, Yagi M, Kanzler I, Sainsbury A, Herzog H, Lin S. PYY3-36 and pancreatic polypeptide reduce food intake in an additive manner via distinct hypothalamic dependent pathways in mice. Obesity (Silver Spring) 21: E669-E678, 2013.
34. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292: E1062-E1068, 2007.
35. Toräng S, Veedfald S, Rosenkilde MM, Hartmann B, Holst JJ. The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo. Physiol Rep 3: e12455, 2015.
36. Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88: 220-224, 2003.
37. Witte AB, Grybäck P, Holst JJ, Hilsted L, Hellström PM, Jacobsson H, Schmidt PT. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 158: 57-62, 2009.